CureVac NV (CVAC) is a pioneering clinical-stage biopharmaceutical company based in Tübingen, Germany, dedicated to advancing innovative therapies utilizing messenger ribonucleic acid (mRNA) technology. With a strong emphasis on harnessing the potential of mRNA for vaccines and therapeutics, CureVac seeks to address unmet medical needs across various disease areas, including infectious diseases and oncology. The company's robust platform and extensive pipeline position it at the forefront of the rapidly evolving mRNA landscape, aiming to deliver transformative solutions to patients worldwide.